KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
NEW YORK, Feb. 09, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Arizona on behalf of investors who purchased INSYS Therapeutics, Inc. (NASDAQ:INSY) securities between March 3, 2015 and January 25, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/insys-therapeutics-inc. There is no cost or obligation to you.
The complaint alleges that INSYS made materially false and misleading statements to investors and/or failed to disclose that: (i) the Company was engaged in the illegal and improper off-labeling marketing of Subsys, a cancer pain treatment; (ii) certain INSYS employees were complicit in an illegal kickback scheme operated for the purpose of increasing prescriptions of Subsys; and (iii) as a result, the Company’s financial statements were materially false and misleading at all relevant times.
On January 25, 2016, the Southern Investigating Report Foundation published an article entitled “The Brotherhood of Thieves: Insys Therapeutics,” alleging that INSYS pressured employees to develop new schemes to promote the illegal and inappropriate off-label use and sale of Subsys.
If you suffered a loss in INSYS you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/insys-therapeutics-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
